<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646122</url>
  </required_header>
  <id_info>
    <org_study_id>Glaucoma Progression with Opti</org_study_id>
    <nct_id>NCT04646122</nct_id>
  </id_info>
  <brief_title>&quot;Predicting Glaucoma Progression With Optical Coherence Tomography Structural and Angiographic Parameters&quot;.</brief_title>
  <official_title>&quot;Predicting Glaucoma Progression With Optical Coherence Tomography Structural and Angiographic Parameters&quot;.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to predict of glaucoma progression. By imaging of the retinal nerve fiber layer RNFL, optic&#xD;
      nerve head (ONH) and macular measurements using spectral-domain OCT (SD-OCT) instruments&#xD;
&#xD;
      ,and detection of optic disc perfusion changes using OCTA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will go a comprehensive ophthalmologic examination including review of medical&#xD;
      history, best-corrected visual acuity (BCVA), slit-lamp biomicroscopy, intraocular pressure&#xD;
      (IOP) measurement, gonioscopy, dilated fundoscopic examination, stereoscopic optic disc&#xD;
      photography, and automated perimetry using Swedish Interactive Threshold Algorithm (SITA&#xD;
      Standard 24-2). Only subjects with open angles on gonioscopy were included.&#xD;
&#xD;
      One eye of each subject will be scanned by a high-speed 1050-nm-wavelength swept-source OCT&#xD;
      instrument.&#xD;
&#xD;
      OCT is providing measurements of the RNFL thickness, ONH, as well as the inner macula for the&#xD;
      assessment of glaucoma progression.&#xD;
&#xD;
      The split-spectrum amplitude-decorrelation angiography (SSADA) algorithm will be used to&#xD;
      compute 3-dimensional optic disc angiography. A disc flow index was computed from 4&#xD;
      registered scans.&#xD;
&#xD;
      Evaluation of progressive changes of the optic disc and RNFL will be based on event-analysis&#xD;
      and/or trend-analysis. In event analysis, progression is defined when the difference between&#xD;
      the baseline and follow-up measurements of the parameter of interest is greater than its&#xD;
      test-retest variability (or the reproducibility coefficient). In trend analysis, regression&#xD;
      analysis is performed between the parameter of interest and time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>retinal nerve fiber layer RNFL</measure>
    <time_frame>one year</time_frame>
    <description>Thickness using OCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>optic nerve head (ONH)</measure>
    <time_frame>one year</time_frame>
    <description>Thickness using OCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disc perfusion changes</measure>
    <time_frame>one year</time_frame>
    <description>flow index using OCTA</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Optical Coherence Tomography Glaucoma</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical Coherence Tomography</intervention_name>
    <description>Optical Coherence Tomography parameters</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will go a comprehensive ophthalmologic examination including review of medical&#xD;
        history, best-corrected visual acuity (BCVA), slit-lamp biomicroscopy, intraocular pressure&#xD;
        (IOP) measurement, gonioscopy, dilated fundoscopic examination, stereoscopic optic disc&#xD;
        photography&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Inclusion criteria:&#xD;
&#xD;
               -  Patients older than 18 years of age with primary open-angle glaucoma (OAG) .&#xD;
&#xD;
               -  Primary OAG (POAG) diagnosed on the basis of IOP measurements more than 21 mmHg,&#xD;
                  open angle on gonioscopy (Grade 3 or 4 on Schaffer grading system for angle&#xD;
                  width), glaucomatous visual field defects consistent with glaucomatous optic disc&#xD;
                  changes.&#xD;
&#xD;
               -  Eyes with baseline macular and ONH OCT images and ONH photographs of adequate&#xD;
                  quality and r performed within 6 months of each other were selected&#xD;
&#xD;
          2. Exclusion criteria:&#xD;
&#xD;
               -  Participants with significant retinal disease.&#xD;
&#xD;
               -  non-glaucomatous optic neuropathy.&#xD;
&#xD;
               -  anomalous discs&#xD;
&#xD;
               -  any retinal pathology. A history of cataract or glaucoma surgery will not be&#xD;
                  exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Fathallah, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asmaa Ali, MD</last_name>
    <phone>01002475442</phone>
    <email>asmaaahmedali@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Khaled Abdelazeem, Phd</last_name>
    <phone>01114001717</phone>
    <email>abdelazeem.h@aun.edu.eg</email>
  </overall_contact_backup>
  <reference>
    <citation>Bussel II, Wollstein G, Schuman JS. OCT for glaucoma diagnosis, screening and detection of glaucoma progression. Br J Ophthalmol. 2014 Jul;98 Suppl 2:ii15-9. doi: 10.1136/bjophthalmol-2013-304326. Epub 2013 Dec 19. Review.</citation>
    <PMID>24357497</PMID>
  </reference>
  <reference>
    <citation>Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006 Mar;90(3):262-7.</citation>
    <PMID>16488940</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 15, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Asmaa Ahmed Ali Youssif</investigator_full_name>
    <investigator_title>Assiut</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

